Tweet
Originally posted by spikefader
-
How can you (or can you) use it for sell signals? -
You bet you can. Bearish PSAR with MFI that hits 30.Originally posted by dmk112
As with everything, r/r setups and discipline management cuz no system is perfect. But check out the stocks that move nicely and you'll see that 20-day characteristic about many/most of them. I wonder how they'd go with MM picks?! Someone should start at thread! lolComment
-
I think tomorrow I'll be looking for an entry. Let's see if it will drop a bit more first.THE SKIRACER'S EDGE: MAKE THE EDGE IN YOUR FAVOR
Comment
-
-
On the daily. I mentioned that yesterday in a reply to a post by Runner.Originally posted by dmk112
I'll be watching it real close tomorrow. What I don't like is that over the past few days the momo guys have been pushing it up in the mornings and then selling off into any strength in the afternoon. I'd like to see $13.75 but I have my doubts. I like it for tomorrow, but will wait to see which way the wind blows.THE SKIRACER'S EDGE: MAKE THE EDGE IN YOUR FAVOR
Comment
-
Sorry dude, I can't keep up with all the posts anymore! It's nuts! hahaOriginally posted by skiracer
13.65-13.85 would be nice.Comment
-
DMK,Originally posted by dmk112
Are you considering an entry?THE SKIRACER'S EDGE: MAKE THE EDGE IN YOUR FAVOR
Comment
-
I'll add back to my ELN position if it drops back to 13.40.Comment
-
-
Healthy wealthy and wise
Elan
Tysabri looks set for Q2 re-launch. Considerable upside in Elan story.
Although Elan is for now a Tysabri-specific story, the pipeline opportunity in Alzheimers Disease (AD) may become more tangible as we progress through 2006. Elan has been working with Wyeth on an innovative AD research programme since 2000. The programme is based on the scientific hypothesis that beta amyloid is a key factor in the development of AD. As such, drugs that target beta amyloid plaques may alter progression of the disease itself rather than providing symptomatic treatment. Two
products from this collaboration are currently in the clinic at Phase I and Phase II. During 2006, Elan/Wyeth will look for signals that are strong enough to propel both products into their next respective phases.
In the meantime, Tysabri remains in the hands of the regulatory agencies. The granting of priority review status in November 2005 underpins the fact that the Food and Drug Administration (FDA) still considers Tysabri to be a very important drug in the MS space. This is the first step in a regulatory pathway which could mean Tysabri being re-launched in the US market by early Q2 2006. Our forecast re-launch of mid-2006 looks comfortable in this context.
We still think it likely that an advisory panel meeting will be convened during the review process. Given the notice that needs to be provided by the FDA to Elan and BiogenIdec on this, such a meeting would occur sometime in Q1 2006. In product-specific terms, the agencies must assess patient safety against patient choice, a balance we continue to believe falls in favour of the product's return.
Watch for Alzheimers newsflow at Elan.
We continue to use our revenue-based sum-of-the-parts (SOTP) model as the primary method to assess valuation – this generates a target of just over 1300c (issued August 9th 2005; previously 870c, issued May 29th 2005) based on a Tysabri re-launch that meets our peak target of $1.6bn in revenues. There is considerable potential upside to this target for 2006, supplied by strong momentum on Tysabri and by progress in the AD programme.
Irish stock brokerage DAVY report on ElanComment
-
Looks like it won't be coming back down and breaking out already, I'm tempted to chase here.Comment
-
Comment
Comment